H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 10.7% of adults in Wilmington have diagnosed diabetes — 1.3 points below the U.S. 12% figure. Census population 115,451. North Carolina Medicare wound biologics: Palmetto GBA (JM). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed Wilmington clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a Wilmington storefront.
Regenerative Medicine for Athletic Performance in Wilmington, NC for clinics & physicians. Compliance support & pricing — contact Hawk Medical.
CDC PLACES (2023, crude) estimates 10.7% of adults in Wilmington have diagnosed diabetes — 1.3 points below the U.S. 12% figure. Census city-proper population is 115,451. If you are adding regenerative medicine for athletes, start with that epidemiology and with Palmetto GBA (JM) — not with a “near me” clinic listing. Hawk Medical ships nationwide; Joe Bradley’s own practice uses the same product classes.
National Regenerative Medicine for Athletic Performance notes (how the product actually works)JM reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Wilmington is 10.7% or not. PLACES is planning data. The LCD is the claim.
We are not going to invent a Wilmington warehouse or a five-star local review. What you get is regenerative medicine for athletes from FDA-registered sources, lot paperwork, and someone who has run the same SOPs in clinic — Joe Bradley. The local numbers on this page are CDC PLACES and CMS JM, not marketing adjectives.
CDC PLACES (2023, crude prevalence) estimates 10.7% of adults — 1.3 points below the U.S. 12% figure. Obesity is 31.9%; arthritis is 26%. That is place-level BRFSS modeling, not a clinic census and not a Wilmington trial.
North Carolina is in CMS MAC JM, administered by Palmetto GBA. CTP and skin-substitute coverage is written at the MAC level. Confirm the current LCD/article before you set utilization — we help practices map product to those rules; we do not override them.
The allograft is used to perform the same basic function in the recipient as in the donor (FDA 361). Using umbilical or amniotic tissue as a marketed “stem cell cure” for unrelated conditions is outside that lane and is a North Carolina compliance risk.
The 96.5% figure is a product-level clinical experience statistic published on our wound-care materials — not a city-specific trial. Your outcomes will depend on patient selection, offloading, and follow-up.
If you operate in North Carolina and another MAC state, say it on the first call. JM will not port 1:1. We would rather split utilization than watch a sister clinic copy Wilmington tickets into the wrong jurisdiction.
Contact us to learn how Hawk Medical supports practices in Wilmington, NC.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for Wilmington is JM geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for Wilmington — 1.3 points below the U.S. 12% figure. Planning input, not an outcomes claim.
North Carolina Part B wound biologics follow this contractor (siblings: SC, VA, WV). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in Wilmington. Useful for joint-program math; still needs a diagnosis and privileging.
No Wilmington storefront. Joe Bradley is an active practice owner. regenerative medicine for athletes stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.